Axoft is differentiated by its ultrasoft Fleuron material, which is orders of magnitude more compliant than standard polyimide probes, addressing the chronic tissue-scarring problem that limits long-term signal stability in conventional intracortical implants. With first-in-human cases completed in 2025, it has advanced further into clinical translation than most materials-science-focused BCI startups at seed stage.